Cgm Dexcom denied as experimental or investigational by Humana?

Humana's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Your Dexcom CGM as Experimental

Humana's experimental or investigational denial means the plan has concluded — based on its own medical policy review — that the Dexcom CGM lacks sufficient clinical evidence for your specific indication or patient population. This framing is sometimes applied when the prescribed use does not match a specific covered indication in Humana's CGM policy, even if the device has broad FDA clearance and robust published evidence supporting its use.

This denial is highly appealable. Dexcom CGM systems carry FDA clearance for diabetes management, and the evidence base supporting CGM use across a wide range of diabetes presentations is well established in peer-reviewed literature and major professional society guidelines. The appeal should demonstrate that your specific use falls within an evidence-supported, guideline-endorsed indication.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline on your Humana denial notice. Humana must decide within 30 days (standard) or 72 hours (urgent/expedited).
• External review (ACA §2719 / ERISA §503): After a final internal denial, you have the right to independent external review — generally within approximately four months. The IRO applies objective clinical and scientific standards, not Humana's internal policy, and its decision is binding.
• Expedited review: If your health situation is urgent, request expedited processing simultaneously with the internal appeal.

## Documentation to Gather

1. FDA clearance documentation: The publicly available FDA 510(k) clearance summary for the specific Dexcom model prescribed, confirming FDA clearance for diabetes management and the cleared indication. 2. Device labeling: The current FDA-cleared labeling confirming the indication under which your prescriber is using the device. 3. Prescriber medical-necessity and evidence letter: Your physician should state that the prescribed use is consistent with the FDA-cleared indication and reference the relevant professional society guidance (e.g., American Diabetes Association, American Association of Clinical Endocrinology) by name — without fabricating statistics. 4. Peer-reviewed literature: Copies of or citations to published clinical studies or systematic reviews supporting CGM effectiveness for your indication, which your prescriber or an appeals specialist can attach. 5. Diagnosis and treatment records: Chart notes, ICD codes, and medication list confirming your clinical context.

## Criteria-Mapping Structure

Obtain Humana's CGM medical policy (available on Humana's website or by written request). Identify the criteria that distinguish a "proven" from an "experimental" indication. For each criterion, document how your case satisfies it: FDA clearance status, published evidence, guideline endorsement, and clinical chart facts. Present this as a structured table or numbered list so the medical reviewer can verify each point without reading through narrative prose.

Experimental denials for FDA-cleared devices with strong guideline backing are among the most successfully appealed denial types at external review. Prepare a thorough submission and file before the deadline.